Glioblastoma patients may benefit from a vaccine-chemotherapy combination
Bottom Line: A vaccine targeting cytomegalovirus (CMV) antigen pp65, combined with high-dose chemotherapy (temozolomide), improved both progression-free survival and overall survival for a small group..










